Parenthetically, as is to be expected, lapatinib, an EGFR and HER2 inhibitor, was similarly effective when given alone or in combination with an NSAID in our basal bladder cancer model (Lubet et al., 2021). This evidence concerns the gene ERBB2 and urinary bladder cancer.